New Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has granted permission to Eli Lilly and Company (India) to conduct a Phase IV clinical trial for its Tirzepatide Solution for Injection in multiple-dose prefilled pens.

This came after the firm presented their proposal along with the Phase IV Clinical Trials Protocol for Tirzepatide 2.5 mg/0.6 ml, 5 mg/0.6 ml, 7.5 mg/0.6 ml, 10 mg/0.6 ml, 12.5 mg/0.6 ml and 15 mg/0.6 ml solution for injection in a multiple-dose prefilled pen before the Committee.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, incl

See Full Page